2025 Q2 -tulosraportti
153 päivää sitten37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
5 000
Myynti
Määrä
70 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 948 | - | - | ||
| 52 | - | - | ||
| 381 | - | - | ||
| 100 | - | - | ||
| 153 | - | - |
Ylin
1,108VWAP
Alin
1,034VaihtoMäärä
1,2 1 126 481
VWAP
Ylin
1,108Alin
1,034VaihtoMäärä
1,2 1 126 481
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenI am relatively new to the stock market and trying to get a better overview. I see that there have been several insider trades in connection with the share issue. Is this normal? What experiences and thoughts do you have about this? Do you find that the insider trades have significant volume, and how do you assess their significance?
·1 t sittenWell... Here, surely everyone has had the opportunity for timeline subscription rights? But easy for me to say, I have months in the company; not years We should also not forget that they daughter with sought-after spisdkompetanse; important with some incentives to retain employees too
·6 t sittenGot some small leftover returns etc. anyone got a good place to invest 6 k?😂- ·10 t sittenWith the low mcap the company will still have after the share issue, it will hardly take much before one can see a strong increase in the company's valuation. So, that the share price could go up several times with an agreement that includes the company being supplied with money is hardly a controversial claim. An mcap of 2-3 billion with a share price increase of approx. 10-fold could be within reach, but dependent on the nature of an agreement. Because then one must also look at the valuation of the remaining potential in the technology. After the completed share issue now, which Wiklund has commented could quickly be the last, there are probably also other share price-triggering news in the near future. I noted Wiklund's positive statement at Aktiespararne about results in the "eye study" with version 3.2/4.0 possibly on par with what had been seen in heart - x40 - and also in CNS, both ongoing internal studies that are coming now during February/March. Since these are internal studies whose development is monitored almost daily, he probably knows more than what has been published, as they have been ongoing for a few months. Everything is set for a very exciting development ahead for the company and the shareholders.·9 t sittenI'm posting this regarding CAR-T from LinkedIn as a continuation of the post above. CAR-T has received more focus at Circio and on page 22 in the slides from Monday, the timelines indicate that R&D collaboration with a CAR-T partner could come already in Q! or Q2 - meaning, just around the corner. This post clearly shows the enormous potential of being able to provide CAR-T with new technology. That's what investors are looking for - it's not available today due to costs and complexity. Only for a few with money. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 1d • In vivo CAR-T isn't just a technical upgrade. It's a complete market reset. Ex vivo CAR-T promised personalized medicine. The actual reality? It created an elite-only therapy accessible to patients near specialized centers with the infrastructure and the budget to support it. The theoretical market was every eligible patient. The actual market is a fraction of that. Investors are finally seeing the gap. In vivo CAR-T changes the equation entirely: • Off-the-shelf delivery, no apheresis centers required • Scalable manufacturing, no patient-specific production • Global reach, including underdeveloped regions • Cost structure that actually supports broad access This isn't incremental improvement. It's democratization of an advanced cure. The clinical proof of concept is already building momentum. Hematological B-cell malignancies remain the core focus, but autoimmune indications are lining up. In vivo CD19 and BCMA CAR-T show promise across Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Myasthenia Gravis. The investment thesis is clear now. Ex vivo carved out a niche for the few. In vivo opens the door to everyone who qualifies medically, not just geographically or economically. When you remove the infrastructure barrier, the addressable market doesn't just grow. It transforms. The companies solving in vivo delivery, persistence, and safety aren't just building better therapies. They're building therapies the world can actually use. That's the shift investors are betting on.
·22 t sittenIt's a deal involving money that is being waited for. The CEO said this at a seminar earlier today: Q: When will this become commercially available? Is it about three years or five years or ... A: If by commercially one means that one can enter into an agreement with a significant upfront payment from a pharmaceutical company, then it is possible within twelve months. If instead one means when we enter the clinic and test the first circRNA candidate in patients – and if development happens as quickly and aggressively as possible – it would be possible to reach patients within two years.·7 t sittenWow... See no reason to argue about this, it just disturbs the thread - Wishing you good luck anyway (But don't want to hear a bad word about gaffer tape, it has saved me from both water in the tarp and bleeding to death after an axe in the foot)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
153 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenI am relatively new to the stock market and trying to get a better overview. I see that there have been several insider trades in connection with the share issue. Is this normal? What experiences and thoughts do you have about this? Do you find that the insider trades have significant volume, and how do you assess their significance?·1 t sittenWell... Here, surely everyone has had the opportunity for timeline subscription rights? But easy for me to say, I have months in the company; not years We should also not forget that they daughter with sought-after spisdkompetanse; important with some incentives to retain employees too
- ·6 t sittenGot some small leftover returns etc. anyone got a good place to invest 6 k?😂
- ·10 t sittenWith the low mcap the company will still have after the share issue, it will hardly take much before one can see a strong increase in the company's valuation. So, that the share price could go up several times with an agreement that includes the company being supplied with money is hardly a controversial claim. An mcap of 2-3 billion with a share price increase of approx. 10-fold could be within reach, but dependent on the nature of an agreement. Because then one must also look at the valuation of the remaining potential in the technology. After the completed share issue now, which Wiklund has commented could quickly be the last, there are probably also other share price-triggering news in the near future. I noted Wiklund's positive statement at Aktiespararne about results in the "eye study" with version 3.2/4.0 possibly on par with what had been seen in heart - x40 - and also in CNS, both ongoing internal studies that are coming now during February/March. Since these are internal studies whose development is monitored almost daily, he probably knows more than what has been published, as they have been ongoing for a few months. Everything is set for a very exciting development ahead for the company and the shareholders.·9 t sittenI'm posting this regarding CAR-T from LinkedIn as a continuation of the post above. CAR-T has received more focus at Circio and on page 22 in the slides from Monday, the timelines indicate that R&D collaboration with a CAR-T partner could come already in Q! or Q2 - meaning, just around the corner. This post clearly shows the enormous potential of being able to provide CAR-T with new technology. That's what investors are looking for - it's not available today due to costs and complexity. Only for a few with money. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 1d • In vivo CAR-T isn't just a technical upgrade. It's a complete market reset. Ex vivo CAR-T promised personalized medicine. The actual reality? It created an elite-only therapy accessible to patients near specialized centers with the infrastructure and the budget to support it. The theoretical market was every eligible patient. The actual market is a fraction of that. Investors are finally seeing the gap. In vivo CAR-T changes the equation entirely: • Off-the-shelf delivery, no apheresis centers required • Scalable manufacturing, no patient-specific production • Global reach, including underdeveloped regions • Cost structure that actually supports broad access This isn't incremental improvement. It's democratization of an advanced cure. The clinical proof of concept is already building momentum. Hematological B-cell malignancies remain the core focus, but autoimmune indications are lining up. In vivo CD19 and BCMA CAR-T show promise across Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Myasthenia Gravis. The investment thesis is clear now. Ex vivo carved out a niche for the few. In vivo opens the door to everyone who qualifies medically, not just geographically or economically. When you remove the infrastructure barrier, the addressable market doesn't just grow. It transforms. The companies solving in vivo delivery, persistence, and safety aren't just building better therapies. They're building therapies the world can actually use. That's the shift investors are betting on.
- ·22 t sittenIt's a deal involving money that is being waited for. The CEO said this at a seminar earlier today: Q: When will this become commercially available? Is it about three years or five years or ... A: If by commercially one means that one can enter into an agreement with a significant upfront payment from a pharmaceutical company, then it is possible within twelve months. If instead one means when we enter the clinic and test the first circRNA candidate in patients – and if development happens as quickly and aggressively as possible – it would be possible to reach patients within two years.·7 t sittenWow... See no reason to argue about this, it just disturbs the thread - Wishing you good luck anyway (But don't want to hear a bad word about gaffer tape, it has saved me from both water in the tarp and bleeding to death after an axe in the foot)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
5 000
Myynti
Määrä
70 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 948 | - | - | ||
| 52 | - | - | ||
| 381 | - | - | ||
| 100 | - | - | ||
| 153 | - | - |
Ylin
1,108VWAP
Alin
1,034VaihtoMäärä
1,2 1 126 481
VWAP
Ylin
1,108Alin
1,034VaihtoMäärä
1,2 1 126 481
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
2025 Q2 -tulosraportti
153 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenI am relatively new to the stock market and trying to get a better overview. I see that there have been several insider trades in connection with the share issue. Is this normal? What experiences and thoughts do you have about this? Do you find that the insider trades have significant volume, and how do you assess their significance?·1 t sittenWell... Here, surely everyone has had the opportunity for timeline subscription rights? But easy for me to say, I have months in the company; not years We should also not forget that they daughter with sought-after spisdkompetanse; important with some incentives to retain employees too
- ·6 t sittenGot some small leftover returns etc. anyone got a good place to invest 6 k?😂
- ·10 t sittenWith the low mcap the company will still have after the share issue, it will hardly take much before one can see a strong increase in the company's valuation. So, that the share price could go up several times with an agreement that includes the company being supplied with money is hardly a controversial claim. An mcap of 2-3 billion with a share price increase of approx. 10-fold could be within reach, but dependent on the nature of an agreement. Because then one must also look at the valuation of the remaining potential in the technology. After the completed share issue now, which Wiklund has commented could quickly be the last, there are probably also other share price-triggering news in the near future. I noted Wiklund's positive statement at Aktiespararne about results in the "eye study" with version 3.2/4.0 possibly on par with what had been seen in heart - x40 - and also in CNS, both ongoing internal studies that are coming now during February/March. Since these are internal studies whose development is monitored almost daily, he probably knows more than what has been published, as they have been ongoing for a few months. Everything is set for a very exciting development ahead for the company and the shareholders.·9 t sittenI'm posting this regarding CAR-T from LinkedIn as a continuation of the post above. CAR-T has received more focus at Circio and on page 22 in the slides from Monday, the timelines indicate that R&D collaboration with a CAR-T partner could come already in Q! or Q2 - meaning, just around the corner. This post clearly shows the enormous potential of being able to provide CAR-T with new technology. That's what investors are looking for - it's not available today due to costs and complexity. Only for a few with money. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 1d • In vivo CAR-T isn't just a technical upgrade. It's a complete market reset. Ex vivo CAR-T promised personalized medicine. The actual reality? It created an elite-only therapy accessible to patients near specialized centers with the infrastructure and the budget to support it. The theoretical market was every eligible patient. The actual market is a fraction of that. Investors are finally seeing the gap. In vivo CAR-T changes the equation entirely: • Off-the-shelf delivery, no apheresis centers required • Scalable manufacturing, no patient-specific production • Global reach, including underdeveloped regions • Cost structure that actually supports broad access This isn't incremental improvement. It's democratization of an advanced cure. The clinical proof of concept is already building momentum. Hematological B-cell malignancies remain the core focus, but autoimmune indications are lining up. In vivo CD19 and BCMA CAR-T show promise across Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Myasthenia Gravis. The investment thesis is clear now. Ex vivo carved out a niche for the few. In vivo opens the door to everyone who qualifies medically, not just geographically or economically. When you remove the infrastructure barrier, the addressable market doesn't just grow. It transforms. The companies solving in vivo delivery, persistence, and safety aren't just building better therapies. They're building therapies the world can actually use. That's the shift investors are betting on.
- ·22 t sittenIt's a deal involving money that is being waited for. The CEO said this at a seminar earlier today: Q: When will this become commercially available? Is it about three years or five years or ... A: If by commercially one means that one can enter into an agreement with a significant upfront payment from a pharmaceutical company, then it is possible within twelve months. If instead one means when we enter the clinic and test the first circRNA candidate in patients – and if development happens as quickly and aggressively as possible – it would be possible to reach patients within two years.·7 t sittenWow... See no reason to argue about this, it just disturbs the thread - Wishing you good luck anyway (But don't want to hear a bad word about gaffer tape, it has saved me from both water in the tarp and bleeding to death after an axe in the foot)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
5 000
Myynti
Määrä
70 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 948 | - | - | ||
| 52 | - | - | ||
| 381 | - | - | ||
| 100 | - | - | ||
| 153 | - | - |
Ylin
1,108VWAP
Alin
1,034VaihtoMäärä
1,2 1 126 481
VWAP
Ylin
1,108Alin
1,034VaihtoMäärä
1,2 1 126 481
Välittäjätilasto
Dataa ei löytynyt